Yale Cancer Center Researchers Identify Possible Target for Immunotherapy in Early-Stage Breast Cancer

Yale Cancer Center researchers used a new molecular analysis tool to detect the level of an important target for immunotherapy in early-stage breast cancers. The diagnostic test, using RNAScope, measures the amount of PD-L1 mRNA in cancer tissues and is devoid of many of the technical issues that plague antibody-based detection methods that have yielded conflicting results in the past. PD-L1 is the target of several novel immune stimulatory therapies in clinical trials.(10.1158/1078-0432.CCR-13-2702)

Bibliography

Author: Robert Slinn

Robert Slinn is ChemSpy's guest columnist. You can read his chemical news updates under the banner "Slinn Pickings". Robert is a Chartered Chemist (CChem), Member of the Royal Society of Chemistry (MRSC) and is a Visiting Researcher in the Department of Chemistry at the University of Liverpool. He has extensive experience in R&D: synthesis, analysis and analytical methods development; troubleshooting, consultancy, and teaching/training methods in industry and in academia. Robert is also 'Physical Methods' author for the Specialist Periodical Report series 'Organophosphorus Chemistry', published by Royal Society of Chemistry, Cambridge, UK. Robert has worked alongside David on the Bedside Book of Chemistry and a major Thomson-Reuters report on the state of the pharmaceutical industry for the 2011 International Year of Chemistry